Long-term treatment with analogues of luteinizing hormone releasing hormone (LHRH) decreases the blood levels of pituitary gonadotrophins which results in a 'medical' castration. The long-term hormonal effects -which are reversibleare the same as those obtained with oophorectomy in young women or orchidectomy in males (Chodak, 1989) . LHRH analogues have recently become commercially available. They have been introduced as an alternative to the mentioned ablative, surgical procedures in premenopausal breast cancer and prostate cancer. However, there has been concern about the economic costs which have been described as high in comparison with surgical castration. This paper presents a comparison of costs for the two methods of castration in patients with advanced prostate cancer. The estimated average cost for orchidectomy was based on data on patients who received such treatment during 1981-86 in Stockholm County, Sweden. We also estimated the average cost of a policy of combining initial LHRH analogue treatment with deferred orchidectomy in long-term responders. Theoretically, this approach might be the most cost-effective policy for castration in advanced prostate cancer since it might obviate the need for surgery in many patients. The analysis was intended only to include costs that are different for surgery compared to medical treatment. Costs for e.g. the clinical follow-up and diagnostic examinations were thus not included because it seemed reasonable to assume that they would be the same irrespective of the type of castration.
Material and methods
The average cost ofsurgical orchidectomy Was estimated using official data on the average duration of the hospital stay in connection with the orchidectomy and the average daily cost according to the Stockholm County Council. Most (Smith et al., 1986; Pavone-Macaluso et al., 1986; Benson & Gill, 1986 [1981] [1982] [1983] [1984] [1985] [1986] Type ofpatient and department 1981-82 1983-86 Average stay (days) (Table II) . Table III shows the average cost per patient of a policy of initial LHRH analogue treatment followed by orchidectomy after 3, 6, 12, 24 or 36 months. An initial LHRH analogue treatment period of about 2 years would result in an average cost that is 26% lower compared to that of initial orchidectomy in all patients (£1,900 versus £2,580). Moreover, surgery would be avoided in about 85% of the patients.
Discussion
Orchidectomy and treatment with LHRH analogues differ in respect to endocrine effects, side-effects and economic costs. There have been reports suggesting a direct effect of LHRH analogues on tumour cells, but in advanced prostate cancer this effect has not been shown to be clinically relevant (Chodak, 1989) . The transient early increase of gonadotrophins after initiation of LHRH analogue therapy has been suggested to precipitate a 'flare' reaction in a small percentage of patients. Such an effect has not been reported following orchidectomy. On the other hand, orchidectomy may be associated with surgical complications, e.g. wound infections or thrombosis. Because of the lack of reliable data costs associated with such complications were not included in this analysis so the average cost for orchidectomy may have been slightly underestimated. LHRH analogues are not associated with any surgical trauma, they have a reversible endocrine effect and may therefore be more acceptable to the patient. In summary, there are advantages and disadvantages with both orchidectomy and LHRH analogues. In such a case the preference of the patient is particularly important and a majority seem to prefer LHRH analogues (Cassileth et al., 1989) . In this paper we have estimated the difference in economic costs for the two alternatives. Economic considerations may be important for the individual patient as well as for society.
It is difficult to reliably compare costs for therapies that are inherently different, e.g. surgery versus medical treatment. For instance, our estimates of the cost for orchidectomy could be criticised because calculations based on official data on the average length of the hospital stay and the average daily cost may not result in an accurate estimate of the actual cost for a surgical orchidectomy. At present there is no widely accepted standard method to calculate such a cost. However, for comparative purposes it is interesting to note that according to the American DRG-system (Diagnosis Related Groups) the cost for a surgical orchidectomy is $3,200 excluding doctors' fees, i.e. the total cost would be about the same as our estimate (£2,580).
We found that the average cost of a surgical orchidectomy was 7-31% lower than the average cost for treatment with a depot LHRH analogue (£2,580 versus £2,760-£3,380). However, the most-cost effective policy for castration was initial LHRH analogue treatment combined with deferred orchidectomy after about 2 years. This approach would decrease the number of surgically treated patients who do not benefit from the treatment because of early progression or intercurrent death and would decrease the cost of the LHRH analogue among patients who become very long-term responders. The average cost was found to be 26% lower compared to a policy of initial surgical orchidectomy in all patients.
It could be argued that the in-hospital stay need not be as long as 7-9 days, i.e. the average length of in-hospital care in Stockholm county during [1981] [1982] [1983] [1984] [1985] [1986] . Theoretically, orchidectomy patients could be admitted on the first day, have surgery on the second, and be discharged on the third day. Such a routine would naturally result in a considerably lower cost (Table II) . However, calculations based on a fixed average daily cost may overestimate the effect of shortening the in-hospital period. In reality the daily cost is the highest during the first days of the stay -i.e. during the day of surgery and the immediate postoperative period -and lower toward the end of the stay when the patient only receives nursing care. The figures used in our calculations represented the actual mean in-hospital period, not how long the inhospital period ought to be in an ideal situation. Only 25% of the patients who were treated with an orchidectomy in Stockholm during 1981-86 were discharged on the first postoperative day. This observation is not surprising in view of the high mean age of the patients (74 years) and their serious disease.
A more extensive use of LHRH analogues instead of orchidectomy would result in fewer beds at departments of surgery and urology being occupied by orchidectomy patients. By extrapolating the mentioned figures for Stockholm county it can be estimated that about 40 surgical beds in Sweden (population 8.5 million) are constantly being occupied by orchidectomy patients.
